Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F9 | P00740 | 10/20 | 0.77 |
| ▸ | F11 | P03951 | 5/20 | 0.77 |
| ▸ | F7 | P08709 | 4/20 | 0.77 |
| ▸ | F10 | P00742 | 3/20 | 0.77 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.61 |
| ▸ | PRMT1 | Q99873 | 5/20 | 0.47 |
| ▸ | EGFR | P00533 | 1/20 | 0.44 |
| ▸ | NQO2 | P16083 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.41 |
| ▸ | F2 | P00734 | 1/20 | 0.40 |
| ▸ | PLG | P00747 | 1/20 | 0.40 |
| ▸ | PLAU | P00749 | 1/20 | 0.40 |
| ▸ | PLAT | P00750 | 1/20 | 0.40 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.40 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.40 |
| ▸ | KDR | P35968 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1232149 | 0.87 | F9 (1.00) | F9F11F7F10CYP2C9 | |
| SCHEMBL9607613 | 0.85 | F9 (0.81) | F9F11F7F10CYP2C9 | |
| SCHEMBL6919610 | 0.85 | F9 (0.79) | F9F11F7F10CYP2C9 | |
| SCHEMBL15291870 | 0.79 | F9 (0.87) | F9F11F7F10CYP2C9 | |
| SCHEMBL1233112 | 0.76 | F9 (1.00) | F9F11F7F10CYP2C9 | |
| SCHEMBL6919026 | 0.75 | F9 (1.00) | F9F11F7F10CYP2C9 | |
| SCHEMBL6918840 | 0.74 | F9 (0.75) | F9F11F7F10CYP2C9 | |
| SCHEMBL6918977 | 0.73 | F9 (0.77) | F9F11F7F10CYP2C9 | |
| SCHEMBL6918463 | 0.72 | F9 (0.76) | F9F11F7F10CYP2C9 | |
| SCHEMBL1232175 | 0.72 | F9 (0.73) | F9F11F7F10CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120136016-A1 | 4, 5, 6-TRISUBSTITUTED PYRIMIDINE DERIVATIVES AS FACTOR IXA INHIBITORS | MERCK SHARP & DOHME LLC | 2012-05-31 | — | — | US | disclosed |
| US-20120136016-A1 | 4, 5, 6-TRISUBSTITUTED PYRIMIDINE DERIVATIVES AS FACTOR IXA INHIBITORS | MERCK SHARP & DOHME LLC | 2012-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120136016-A1 | 4, 5, 6-TRISUBSTITUTED PYRIMIDINE DERIVATIVES AS FACTOR IXA INHIBITORS | F9, F8, F12 | F9 1/4885F11 5/4885F7 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.